CWG
VTVT icon

C WorldWide Group’s vTv Therapeutics VTVT Stock Holding History

C WorldWide Group’s Portfolio VTVT Stock Details VTVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,205
Closed -$74K – 134
2018
Q2 		$74K Sell
1,205
-1,244
-51% -$91.9K ﹤0.01% 131
2018
Q1 		$399K Buy
+2,449
New +$599K 0.01% 113

Other funds holding VTVT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ARTA
A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

C WorldWide Group's VTVT Position: Q3 2018 in Review

C WorldWide Group sold out of vTv Therapeutics (VTVT) in Q3 2018, closing a stake of 1,205 shares — an estimated $74K sold.

C WorldWide Group first reported a position in VTVT in Q1 2018 and held it in 2 quarters. The position peaked at $399K in Q1 2018. 19 funds tracked by Wall St. Rank hold VTVT as of Q3 2018.

  • C WorldWide Group reported no remaining vTv Therapeutics position as of Q3 2018 after selling out during the quarter.
  • C WorldWide Group sold 1,205 vTv Therapeutics shares in Q3 2018, an estimated $74K.
  • C WorldWide Group first reported a position in vTv Therapeutics in Q1 2018 and held it in 2 quarters.
  • C WorldWide Group's vTv Therapeutics position peaked at $399K in Q1 2018.
  • 19 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2018.

Based on C WorldWide Group's 13F filing for Q3 2018, filed 5 Nov 2018.